Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12626001373369
Ethics application status
Approved
Date submitted
9/10/2026
Date registered
16/11/2026
Date last updated
16/11/2026
Date data sharing statement initially provided
16/11/2026
Type of registration
Prospectively registered
Titles & IDs
Public title
Evaluation of subcutaneous injections of benzathine penicillin G for prevention of recurrent cellulitis
Query!
Scientific title
Evaluation of subcutaneous injections of benzathine penicillin G for prevention of recurrent cellulitis
Query!
Additional trial identifiers [1]
318621
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SCIP Cellulitis
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Cellulitis
343826
0
Query!
Recurrent cellulitis
343827
0
Query!
Condition category
Condition code
Infection
339968
339968
0
0
Query!
Other infectious diseases
Query!
Skin
340162
340162
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Patients with current or recent lower leg cellulitis will be invited to participate and will receiving a dose of subcutaneous 10.8 million units of benzathine penicillin G (termed 'SCIP').
The drug administered is BPG: Bicillin® L-A (Pfizer).
Each vial contains 1.2MU BPG.
Participants will receive 10.8MU equal to 9 vials (20.7mL).
Frequency: Once every 10 weeks (dependent on ongoing participation as below)
Administered in clinic by medical staff (nurse or medical practitioner)
Participants will be invited to return to clinic at the 10 week mark, at which stage they will be offered to participate in either i) ongoing 10 weekly administration of subcutaneous benzathine penicillin G at the same dosing and frequency as above, ii) transitioning to oral prophylaxis with 250mg tablet once daily phenoxymethylpenicillin (standard care for recurrent cellulitis) to complete the 52 week trial period or iii) nil further treatment intervention. This choice will be actively offered only at the 10 week review following initial SCIP. Follow-up in all the above arms will occur out to 52 weeks from enrolment.
Query!
Intervention code [1]
335527
0
Prevention
Query!
Intervention code [2]
335528
0
Treatment: Drugs
Query!
Description of the comparator or control
Nil treatment following the initial 10-week intervention.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
347136
0
The frequency of adverse events that are causally related to SCIP administration
Query!
Assessment method [1]
347136
0
Adverse events will be detected on clinical examination and from participant self-reporting identified by auditing patient medical records. Root cause analysis of reported adverse events will determine causality. These will be combined as a composite assessment for this outcome. Theoretical adverse effects are localised pain, erythema, oedema and skin necrosis. Systemic adverse effects include allergic reaction similar to other routes of administration.
Query!
Timepoint [1]
347136
0
Baseline and daily until the end of the study period (52 weeks post initial dose)
Query!
Secondary outcome [1]
469089
0
The self-reported tolerability of SCIP administration
Query!
Assessment method [1]
469089
0
Participant surveys designed for this trial addressing experiences of participant using 5 point Likert scale to rate comfort with SCIP and preference to continue SCIP.
Query!
Timepoint [1]
469089
0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Query!
Secondary outcome [2]
469090
0
Time plasma penicillin concentrations remain greater than 10ng/mL between SCIP doses
Query!
Assessment method [2]
469090
0
Dried blood spot assays using fingerpick sampling for plasma penicillin concentrations to model individual time greater than 10ng/ml, based on a population PK model (incorporating inter-occasion variability).
Query!
Timepoint [2]
469090
0
Dried blood spots collected following first SCIP administration, daily following first SCIP dose until discharge, immediately prior to next SCIP dose (if electing further SCIP doses), 2 weeks following 2nd dose (and further)
Query!
Secondary outcome [3]
469092
0
Proportion of subjects presenting to hospital with an acute episode of cellulitis
Query!
Assessment method [3]
469092
0
Review of medical records
Query!
Timepoint [3]
469092
0
Routinely every 4 weeks during study period out to 52 weeks
Query!
Secondary outcome [4]
469093
0
Participant pain score of subcutaneous injections
Query!
Assessment method [4]
469093
0
Numerical rating scale for pain (10 point)
Query!
Timepoint [4]
469093
0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Query!
Secondary outcome [5]
469102
0
Tolerability measured as oedema
Query!
Assessment method [5]
469102
0
Numerical rating score of oedema (4 point)
Query!
Timepoint [5]
469102
0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Query!
Secondary outcome [6]
469103
0
Tolerability measured as erythema
Query!
Assessment method [6]
469103
0
Numerical rating score for erythema (4 point)
Query!
Timepoint [6]
469103
0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Query!
Eligibility
Key inclusion criteria
Adults with a current or recent (in preceding 3 years) diagnosis of cellulitis.
Admitted as an inpatient or attending as an outpatient at Fiona Stanley Hospital
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
- Have a history of adverse drug reaction, hypersensitivity or allergy to penicillin;
- Documented cognitive impairment or history of dementia leading to incapacity;
- Have scarring or dermatological conditions affecting skin integrity at the intended site of SCIP administration;
- Planned to receive greater than two (2) weeks of antimicrobials with a beta-lactam as a backbone; or
- Inappropriate to be involved with the study as deemed by the treating team.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2027
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/07/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2028
Query!
Actual
Query!
Sample size
Target
24
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
30427
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
46846
0
6150 - Murdoch
Query!
Funding & Sponsors
Funding source category [1]
323195
0
Government body
Query!
Name [1]
323195
0
South Metropolitan Health Service
Query!
Address [1]
323195
0
Query!
Country [1]
323195
0
Australia
Query!
Funding source category [2]
323197
0
University
Query!
Name [2]
323197
0
Curtin University
Query!
Address [2]
323197
0
Query!
Country [2]
323197
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
A/Prof. Laurens Manning- Fiona Stanley Hospital
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
326165
0
None
Query!
Name [1]
326165
0
None
Query!
Address [1]
326165
0
Query!
Country [1]
326165
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
321598
0
WA Health Central HREC
Query!
Ethics committee address [1]
321598
0
https://www.health.wa.gov.au/Articles/U_Z/WA-Health-Central-HREC
Query!
Ethics committee country [1]
321598
0
Australia
Query!
Date submitted for ethics approval [1]
321598
0
10/03/2026
Query!
Approval date [1]
321598
0
29/06/2026
Query!
Ethics approval number [1]
321598
0
Query!
Summary
Brief summary
Admissions for recurrent cellulitis represent a significant burden to the healthcare system. One strategy for prevention includes the use of prophylactic antibiotics, commonly oral penicillin. There is increasing evidence that subcutaneous administration of high doses of benzathine penicillin G (also known as SCIP), as an alternative to intramuscular administration is effective, well tolerated and achieves favourable serum concentrations. This is an unblinded, non-randomised, opt-in, open-label phase IIa clinical trial to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneous BPG for the prevention of cellulitis. The goal is to provide a potential alternative method of prophylaxis for recurrent cellulitis. We hypothesis that SCIP will be a safe and tolerable alternative for cellulitis prophylaxis.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
154210
0
A/Prof Laurens Manning
Query!
Address
154210
0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Query!
Country
154210
0
Australia
Query!
Phone
154210
0
+61 8 6151 1146
Query!
Fax
154210
0
Query!
Email
154210
0
[email protected]
Query!
Contact person for public queries
Name
154211
0
Laurens Manning
Query!
Address
154211
0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Query!
Country
154211
0
Australia
Query!
Phone
154211
0
+61 8 6151 1146
Query!
Fax
154211
0
Query!
Email
154211
0
[email protected]
Query!
Contact person for scientific queries
Name
154212
0
Laurens Manning
Query!
Address
154212
0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Query!
Country
154212
0
Australia
Query!
Phone
154212
0
+61 8 6151 1146
Query!
Fax
154212
0
Query!
Email
154212
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF